GlobeNewswire by notified

Conagen commercializes scalable sweetness enhancers from nature

Share

Teams up with pipeline partner Sweegen for bridging natural solutions with mainstream taste.

Bedford, Mass., July 08, 2022 (GLOBE NEWSWIRE) -- Conagen, the Massachusetts-based biotech firm, announced the commercialization of an expansive portfolio of natural sweetness enhancers for taste modification in sugar reduction solutions for food and beverages. The enhancers are made with precision fermentation, a technology that has led to the innovation of an extensive platform of phenolic antioxidants.

Sweetness enhancers in the market today are made by chemical synthesis or by using an organic solvent extraction method, both of which are time-consuming, labor-intensive, and environmentally unfriendly. Conagen’s precision fermentation method is a preferred, clean, and sustainable method for developing sweetness enhancement compounds.

“These unique molecules are yet another example of how Conagen leverages its molecular platforms and precision fermentation capabilities to create useful ingredients for food and beverage applications. Our ability to rapidly scale modern, clean and sustainable sweetness enhancers provides additional and better options for taste modulation and sugar reduction beyond those enabled by the non-caloric sweeteners already on the market,” said Casey Lippmeier, Ph.D., vice president of innovation at Conagen.

Conagen’s sweetness enhancers belong to a group of natural product molecules called phenolic compounds, found extensively in many plant species. Phenolic compounds are commonly found in vegetables and fruits and are a significant part of the human diet. They are biosynthesized by plants and lichens as secondary metabolites and comprise a diverse group of phytochemicals.

Increasing consumer awareness of chronic diseases such as obesity and diabetes sparks the market pull trend toward zero sugar and low-to-no calorie food and beverages and is expected to continue upward. The health trend drives the growth in new sweetness enhancer technologies for an ever-demanding sugar reduction solutions market. Consumers are seeking ways to improve their diets and are increasingly interested in natural and clean ingredients.

Conagen and its pipeline partner Sweegen, a global leader in wellness-based sugar reduction solutions, have previously teamed up to develop modern natural sweeteners that can replace up to 100% sugar in particular food and beverage applications and bitter blockers to mitigate up to 80-100% bitterness in consumer trending products, such as energy drinks, sauces, and confectionery products with low to no sugar.

“Together, with Conagen, we’re building a bridge of natural solutions with mainstream taste,” said Casey McCormick, head of global innovation at Sweegen. “These new molecules can modulate mouthfeel and boost the sensation of the sweetness of other sweeteners and flavors in food and beverages, leading to a significant reduction in sugar usage.”

McCormick further stated, “Conagen is an ideal innovation partner for Sweegen to continuously build our robust and powerful portfolio and pair it with our first-class sweetener systems. The more sweetness enhancers in our toolbox, the better our exploration and discovery of new ways for food and beverage brands to make healthier products that taste great and resonate with consumers.”

Sweegen has a long-standing partnership with biotechnology innovator Conagen. Conagen focuses on developing sustainable, nature-based ingredients that improve existing options in the market or represent completely novel ingredient solutions.

###

About Conagen
Conagen is a product-focused synthetic biology R&D company with large-scale manufacturing capabilities. Our scientists and engineers use the latest synthetic biology tools to develop high-quality, sustainable, nature-based products by precision fermentation and enzymatic bioconversion. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. www.conagen.com

About Sweegen
Sweegen provides sweet taste solutions for food and beverage manufacturers around the world. 

We are on a mission to reduce the sugar and artificial sweeteners in our global diet. Partnering with customers, we create delicious zero-sugar products that consumers love. With the best modern sweeteners in our portfolio, such as Bestevia® Rebs B, D, E, I, M, and N, and brazzein, along with our deep knowledge of flavor modulators and texturants, Sweegen delivers market-leading solutions that customers want, and consumers prefer. Well. Into the Future. 

For more information, please contact info@sweegen.com and visit Sweegen’s website, www.sweegen.com.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Baltic Horizon Fund consolidated audited results for 202329.3.2024 10:35:00 CET | Press release

Management Board of Northern Horizon Capital AS has approved the audited financial results of Baltic Horizon Fund (the Fund) for the year 2023. The financial results remained unchanged compared to the preliminary disclosure on 15 February 2024. Executing our strategy In a challenging economic landscape characterized by inflation, interest rate volatility, and recent geopolitical events, the Fund has assessed various strategic options to navigate these complexities and ensure future growth. Over the past year, our focus has been on reshaping our strategy to foster sustainable value, concentrating efforts on avenues that promise reliable and consistent growth for our investors. In light of prevailing market conditions, we firmly believe that the execution of the ‘Modern City Life’ strategy, introduced to investors in summer 2023, is paramount to their best interests. In the coming years, we expect two thirds of the Fund’s NOI to come from the centrally located ‘Modern City Life’ multi-fu

Progress on ABN AMRO share buyback programme 22 – 28 March 202429.3.2024 08:00:00 CET | Press release

Progress on ABN AMRO share buyback programme 22 – 28 March 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 22 March 2024 up to and including 28 March 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €15.47 for a total amount of €46,409,760.00. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly reports, see the ABN AMRO website at https://www.abnamro.com/en/investor-relations/information/share-buyback-programme. To date the total consideration for shares and depositary receipts repurchased amounts to €279,519,000.00 representing 55.9% of the overall share buyback programme. ABN AMRO Press Office pressrelations@nl.abnamro.com +31 20 6288900ABN AMRO Investor Relations investorrelations@nl.abnamro.com +31 20 6282282 This press release is published by ABN AMRO Ba

Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind29.3.2024 07:00:00 CET | Press release

Press release Brussels, 29 March 2024 Regulated information – Inside information Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind On 20 November 2023, Orange Belgium SA (the “Company”) received notification from Nethys SA (“Nethys”) of its wish to contribute its 25% + 1 shareholding in VOO Holding SA (“VOO”) to the capital of the Company, provided that such contribution results in Nethys holding at least 11% of the Company's share capital (after contribution), pursuant to the provisions of the shareholders' agreement entered into by and between the Company, Atlas Services Belgium SA (“ASB”) and Nethys on 2 June 2023. Nethys can be considered a “related” party to the Company within the meaning of the IAS standards, as it has significant influence over VOO within the meaning of IAS and VOO is part of the group to which the Company belongs. Date and value of the planned t

McWhorter Foundation Combats Nelson Peltz’s Outdated Ideologies and Advocates for Sustainable Inclusivity In Corporate Leadership29.3.2024 06:59:56 CET | Press release

PALM BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- C.K. McWhorter, chairman of the McWhorter Foundation, voices concerns over outdated perspectives in corporate leadership, exemplified by recent remarks from Nelson Peltz regarding Disney's film direction. After encountering instances of racism and exclusivity on Town of Palm Beach Island (known as home to Jeffrey Epstein, Nelson Peltz and others), McWhorter reflects on the disconnect between elite boardroom discussions and the realities faced by diverse communities. While briefly meeting Nelson Peltz and shaking hands after both departed separate lunches, McWhorter initially respected his insights. However, recent comments made by Peltz suggesting Disney should avoid inclusive films have raised eyebrows and prompted McWhorter to speak out. "It's concerning when influential figures like Peltz advocate against inclusivity in entertainment," McWhorter comments. "The future is in diversity and representation, especially as millennial a

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates29.3.2024 05:24:27 CET | Press release

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue was approximately RMB1,503 million during 2023. The revenue from pharmaceutical products increased by approximately 58% compared to 2022. The sales revenue of TUOYI® (toripalimab) was approximately RMB919 million, representing an increase of approximately 25% compared to the previous year.Total research and development (“R&D”) expenses were approximately RMB1,937 million in 2023, representing a decrease of approximately 19% compared to 2022. The decrease in R&D expenses was mainly due to the strategic management of R&D investments in certain early-stage pipelines, while optimizing resource all

HiddenA line styled icon from Orion Icon Library.Eye